{"entity":{"id":"nct05141149","kind":"trial","name":"First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer","aka":[],"tldr":"A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Prestige Biopharma Limited, active and no longer recruiting.","summary":"First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer is a phase 1/2 interventional study registered as NCT05141149 by Prestige Biopharma Limited, with 80 participants enrolled, started 2023-06-05 and due to reach its primary completion in 2026-07. Interventions recorded: PBP1510 (400mg/16mL) and Gemcitabine (1000 mg/m^2).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05141149","url":"https://clinicaltrials.gov/study/NCT05141149"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic","metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine","pbp1510"],"companies":["prestige-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05141149","phase":"1/2","setting":"A First in Human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients With Advanced/Metastatic Pancreatic Cancer","sponsor":"Prestige Biopharma Limited","participation":[{"nct":"NCT05141149","source":"https://clinicaltrials.gov/study/NCT05141149","fetchedAt":"2026-10-07T16:53:34.728Z","studySha256":"d4adc8659d30b380a9bee6971c3a2751e9ca33f406942451f00a80162e91ed1d","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-07-27","leadSponsor":"Prestige Biopharma Limited","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":80,"enrolmentType":"ESTIMATED","siteCount":4,"recruitingSiteCount":0,"countries":["Australia","Singapore","Spain","United States"]}],"started":"2023-06-05","startedType":"actual","enrolled":80,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05141149/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"pbp1510","kind":"drug","name":"PBP1510","route":"/drugs/pbp1510/"}],"company":[{"id":"prestige-biopharma","kind":"company","name":"Prestige Biopharma","route":"/companies/prestige-biopharma/"}]}}